ALT Altimmune Inc

Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate at the following investor conferences:

• Evercore ISI 5th Annual HealthCONx Virtual ConferenceTuesday, November 29, 2022Fireside chat at 10:55 am Eastern Time

• Piper Sandler 34th Annual Healthcare Conference in New York, NYThursday, December 1, 2022Fireside chat at 10:00 am Eastern Time

The sessions will be webcast and can be accessed by visiting the Events section of the Altimmune website.

About Altimmune

Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company’s lead product candidate, pemvidutide (ALT-801), is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedInFollow @AltimmuneInc on Twitter

Altimmune Investor & Media Contact:

Richard EisenstadtChief Financial OfficerPhone: 240-654-1450reisenstadt@altimmune.com